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ABSTRACT
Pancreatic cancer (PC) still represents an unresolved therapeutic challenge due to the associated poor 
prognosis and the lack of responsiveness to current treatments. Surgery, followed by adjuvant therapy, 
is the only potentially curative treatment for PC; however, only 20% of PC patients have a potential 
resectable disease at diagnosis and the overall 5-year survival rate does not exceed 20%. In this context, 
better, more effective strategies are needed. Immunotherapy is an interesting approach for cancer 
treatments, but increasing evidence testifies that the immune system plays contrasting roles in both tumour 
elimination and tumour progression. In particular, PC is considered relatively immune resistant due to the 
characteristic fibrosis, the presence of immunosuppressive cells, and the compact extracellular matrix 
that defines the tumour microenvironment and allows for the growth of cancer cells. Despite this, there 
is evidence that PC cells are able to induce an anti-tumour immune response that can impact the disease 
course. More recently, it has become clear that PC activates both the anti-cancer immune response and 
the immune suppressive effects of the immune system; therefore, for the immune-therapeutic strategies 
to be effective, they should involve not only the stimulation of the immune system but also the control of 
the immune suppressive milieu. In this review, we discuss the dual role of immune cells in the onset and 
progression of PC.
Keywords: Pancreatic cancer (PC), immune response, immunotherapy, T cells, regulator T cells (Treg), 
natural killer (NK) cells, dendritic cells (DC), macrophages, myeloid derived suppressor cells (MDSC), 
mast cells (MC).
INTRODUCTION
Pancreatic cancer (PC) still represents an 
unresolved therapeutic challenge due to the 
associated poor prognosis and the lack of 
responsiveness to current treatments. Surgery, 
followed by adjuvant therapy, is the only 
potentially curative treatment for PC, but only 
20% of PC patients have a likely resectable disease 
at diagnosis and the overall 5-year survival rate 
does not exceed 20%.1 In this context, better, more 
effective strategies are needed. Several published 
data confirm that innate and adaptive immune cells, 
as well as effector molecules and pathways, can 
perform tumour suppressive mechanisms. However, 
we know that the immune system can also favour 
tumour progression. The Janus-faced role of the 
immune system is well-described by the dynamic 
process termed ‘cancer immunoediting’ (Figure 1).2 
Anti-tumour immune responses are carried out 
by both innate and adaptive immune system 
components, such as immune cells, cell surface 
molecules, costimulatory receptors, ligands, and 
cytokines. The innate immune cells principally 
involved in the fight against cancer are granulocytes, 
macrophages, natural killer (NK) cells, and dendritic 
cells (DC). These cells represent the first line of 
defence against invading and transformed cells, 
even though cancer cells can easily escape their 
surveillance. Other than this initial defence, the 
adaptive arm of the immune system, mainly 
represented by T and B lymphocytes, is the most 
important force against cancer and has the ability 
to recognise cells expressing foreign antigen-like 
neoplastic cells. Moreover, immunosuppressive 
cytokines and regulatory cell populations, including 
regulatory T cells (Treg) and tumour associated 
macrophages (TAM), can favour tumour growth. 
In this context, the action of the hosts’ immune 
response against tumours can be demonstrated 
by the presence of immune components in situ. 
Analysis of the density, location, and functional 
properties of all immune cell types that may be 
found in pancreatic tumour tissue has allowed 
the identification of the components that exert an 
anti-tumour or a tumour-supportive role in 
patients (Figure 2).
Figure 1: The three phases of the cancer immunoediting theory: Elimination, Equilibrium, and Escape. 
Elimination: The effector immune cells successfully eradicate the developing tumour. Equilibrium: The tumour 
cells and the host immune system are in balance; the adaptive immune system controls tumour growth, although 
shaping tumour immunogenicity. Escape: The tumour overcomes the immune system and becomes a clinically 
evident disease. 
CTL: cytotoxic lymphocytes; DC: dendritic cell; IFN: interferon; IL: interleukin; Mø: macrophage; MDSC: myeloid-derived 
suppressor cell; MHC: major histocompatibility complex; NK: natural killer cell; NKT: natural killer T cell; 
PD-1: programmed cell death 1: TNF: tumournecrosis factor; Treg: T regulatory cell; TGF: transforming growth factor.
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From an immunological perspective, PC is 
considered an incredibly peculiar cancer type. 
It is well known that inflammation drives PC 
development and progression; >90% of all 
pancreatic adenocarcinomas carry an activating 
mutation in the RAS oncogene, which drives an 
inflammatory programme.3 In addition, chronic 
inflammation (pancreatitis) is a documented 
risk factor for PC development.4 Although often 
characterised by a marked leukocyte infiltration,4 
levels of intratumoural effector immune cells are 
limited in PC compared to other cancers.5,6 The 
lack of effective immunity accompanies a massive 
infiltration of immune suppressive leukocytes and 
the presence of tumour supportive immune cells. 
Usually, the PC stroma encompasses the majority 
of the tumour mass and consists of a dynamic 
assortment of extracellular matrix components 
and non-neoplastic cells, including fibroblasts, 
vascular cells, and immune cells. In particular, 
the expansion of the tumour is associated with 
a substantial desmoplastic stromal reaction that 
changes the normal pancreatic architecture 
into fibrotic tissue; this fibrotic tissue primarily 
represents a barrier for the immune system but 
also interacts with neoplastic cells, favouring 
its development.7
The PC microenvironment develops an 
immunosuppressive phenotype, as demonstrated 
by the large infiltration of Treg and myeloid-derived 
suppressor cells (MDSC) present at the early stage 
of the disease. In advanced PC, T lymphocytes 
(CD4+ and CD8+) are rarely found in the tumour 
tissue.8 In all stages of the disease, a strong inverse 
correlation between MDSC and CD8+ T cells 
persists, suggesting that MDSC are a mediator of 
tumour immune suppression.8 Nevertheless, PC is 
able to activate an anti-tumour immune response; 
firstly, the accumulation of CD8+ T cells in PC 
correlates with survival of patients9 and, secondly, 
the PC cells can express tumour-associated 
antigens10,11 that are immunogenic and able to elicit 
a specific immune response. For example, PC 
patients can show intratumoural and circulating 
alpha-enolase-specific T cells, and the presence 
of anti-alpha-enolase antibodies correlates with a 
significantly better clinical outcome in advanced 
patients treated with standard chemotherapy.11-13 
For these reasons, despite both clinical and animal 
models showing strong evidence for inhibition of 
immune function in PC, patients can be candidates 
for immunotherapies, involving strategies that use 
stimulation of the immune system in order to control 
the tumour immune suppressive microenvironment.
ANTI-TUMOUR IMMUNE CELLS 
IN PANCREATIC CANCER
Effector T Cells 
CD3+ T cells recognise antigens of cancer cells and 
are divided into either CD8+ cytotoxic lymphocytes 
(CTL) or CD4+ T helper (Th) cells that recognise 
peptides presented by the major histocompatibility 
complex (MHC)-I or MHC-II, respectively. The Th 
cells are divided into various subsets, including 
interferon (IFN)-γ and tumour necrosis factor 
(TNF)-α producing cells (Th1), interleukin (IL)-4, 
IL-5, and IL-13 expressing cells (Th2), T follicular 
helper cells (Tfh), IL-17 expressing cells (Th17), 
IL-9+ (Th9), IL-22 producing cells (Th22), and Treg. 
In addition, CTL subsets, including Tc1, Tc2, Tc17, 
and regulatory CD8+ T cells, have been defined. 
All these T lymphocyte subsets have been 
investigated for their implications in cancer 
development and anti-tumour immunity; due to 
their ability to produce IFN-γ and directly kill 
target cells, CTL are the critical mediators of the 
anti-tumour response.2 
CD3+ T infiltrating lymphocytes (TIL) have 
been detected in human and mouse PC tissue 
specimens.8,14 Interestingly, the study of TIL 
distribution, density, and function in the tumour 
microenvironment reveals their anti or pro-tumour 
activity.6 In the case of PC, TIL do not usually 
reach the tumour cells in a consistent number, 
remaining confined in the peritumoural tissue.14 
One explanation for poor CTL infiltration may be 
the lack of neoantigen expressed by PC cells.15 
Moreover, it can be due to the effects of the stroma 
and suppressor immune cells.16 
The presence of TIL in PC was reported for the 
first time by Ademmer et al.17 They documented 
that lymphocytes were most often confined as 
agglomerates in the fibrotic interstitial tissue, while 
rare cells could be found among the epithelial 
neoplastic cells. The percentage of lymphocytes 
was changeable between samples; however, there 
was a predominance of T cells with a CD45RO+ 
memory phenotype. Among the TIL, the memory 
CTL exert the major antitumour effects and their 
frequency in resected PC was found to correlate 
with survival.18
The role of Th cells in tumours is more complicated 
than the role of CTL because their protective or 
supporting role towards cancer cells depends on 
their functional profile. For example, Th2 cells take 
part in tumour tolerance,6 while Th1 cells antagonise 
tumour growth through the production of IL-2 and 
IFN-γ, required for the activation and proliferation 
of CTL activity.19,20 Overall, memory T cells and/or 
T cells with a Th1 phenotype are associated with a 
better prognosis.21
The role of Th17 cells in tumourigenesis has not 
been clarified. Both animal models and clinical 
studies have suggested functions for Th17 cells 
(and related cytokines) in tumour development. 
He et al.22 detected Th17 cells in pancreatic tumour 
tissues and showed that the frequency of Th17 
cells was significantly higher in the lymphocytes 
infiltrating the PC than the adjacent tissue; 
in addition, the number of Th17 cells was 
associated with tumour stages.22 We have recently 
demonstrated that ENO1-specific Th17 cells have a 
specific anti-cancer effector function in PC patients, 
and that there are decreased levels of these cells in 
cancer compared to healthy mucosa.12
The recently discovered subset of Th lymphocytes, 
named Th9 cells, secrete IL-9 together with IL-21 
and play a role in several inflammatory disorders. 
These cells arise from reprogrammed Th2 cells 
upon stimulation with IL-4 and transforming 
growth factor (TGF)-β.23 Th9 cells feature potent 
anticancer properties,24,25 but currently there are no 
data on their role in PC. Natural killer T (NKT) cells 
are a small subpopulation of T lymphocytes with 
antigen-specific T cell receptors (TCR) that 
recognise both self antigens and foreign antigens, 
providing a mechanism to identify lipid antigens that 
are not detected by CD4+ and CD8+ T lymphocytes. 
In cancer, these cells were initially considered 
to exert a defensive role, but in recent studies 
they have been found to also inhibit anti-tumour 
responses. It is now more clear that this dual 
role depends on the presence of two different 
subpopulations of NKT cells with distinguished 
functions: Type I NKT cells with an invariant TCR 
and Type II NKT cells with more variable TCR. 
Type I NKT cells support tumour immunity through 
the production of IFN-γ, activating NK cells, 
CTL cells, and DC to produce IL-12. Conversely, 
Type II NKT cells, distinguished by differing TCR 
(recognising lipids presented by CD1d), principally 
obstruct tumour immunity.26 Statistically significant 
lower numbers of peripheral blood NKT cells 
were found in patients with a variety of cancers 
compared to healthy subjects.27 Nagaraj et al.28 
attempted to enhance the anti-tumour effect 
against PC by supplementary triggering of NKT cells 
in vivo; they established a significant expansion of 
Figure 2: Diagram of cell types that interact with cancer cells in the tumour microenvironment. 
Immune cells that exert an anti-pancreatic cancer effect are CD8+ cytotoxic lymphocytes, natural killer T 
cells, CD4+ T helper (Th1, Th9, Th17), natural killer cells, and dendritic cells. Cells with a pro-pancreatic cancer 
role are Th2, Th22, T regulatory cells, myloid-derived suppressor cells, tumour-associated macrophages, 
cancer associated fibroblasts, and mast cells.
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IFN-γ-producing NKT cells correlates with reduced 
tumour growth.
Natural Killer Cells 
NK cells are innate lymphocytes known as the 
first-line of defence against infections and 
neoplasia due to their ability to exert direct cellular 
cytotoxicity, without prior sensitisation, and to 
secrete immunostimulatory cytokines like IFN-γ. 
Their ability to spontaneously kill tumour cells 
and to activate other immune cells highlights the 
importance of their role in fighting primary tumours 
and metastases. Apart from conventional NK cells, 
there is a range of tissue-resident NK cells with 
considerable differences in terms of their origin, 
development, and/or function.29 The discovery of 
the diversity among NK cells, and the newly arising 
innate lymphoid cells (ILC), in general led to a newly 
proposed nomenclature; thus, conventional NK 
cells are classed as belonging to the Group 1 ILC, 
distinguished from ILC2, ILC3, and other non-NK 
cell ILC1 subsets by their dependence on IL-15 and 
their intrinsic cytotoxic capacity.30 The scanning 
mechanism of NK cells is what allows them 
to maintain surveillance of tumour cells and 
virus-infected cells. 
Through MHC Class I loss, a common event in PC,31 
PC cells become the target of NK cells, even if 
they can escape from this control system. Indeed, 
activating receptors, such as NKG2D, are reduced on 
the surface of NK cells in patients with PC and these 
lower levels are associated with advanced disease.32 
Higher absolute levels of NK cells in the circulation 
were associated with a better prognosis in a small set 
of 13 patients with PC,33 indicating that the immune 
system, through NK cells, still exerts some control on 
cancer growth despite disease progression.
Dendritic Cells
DC are important for immune surveillance and 
play a key role in cancer immunosurveillance. 
Indeed, induction of an effective anti-tumour 
response requires the active participation of host 
antigen presenting cells, such as DC, responsible for 
the presentation of tumour-specific antigens with 
the ability to elicit primary immune responses. DC 
are divided into two subsets: myeloid CD11c+ DC 
(DCs1) and lymphoid CD11c− DC (DCs2), which have 
been shown to regulate immune responses via the 
polarisation of Th1, Th2, or even Th3 differentiation 
under the influence of cytokines produced by 
themselves. For this reason, some biological 
response modifiers used in anticancer therapy 
upregulate the activity of DCs1, but not DCs2 
activity.34 In patients with PC, DC presence is 
associated with a better prognosis,35 even if 
their number and function, in particular of DCs1, 
is decreased and defective, limiting their ability to 
present foreign antigens to T cells.
IMMUNE CELLS WITH 
PRO-PANCREATIC CANCER ACTIVITY 
Tumour-supportive T Lymphocytes
Treg are a subset of T lymphocytes, characterised 
by the expression of the transcription factor 
forkhead box protein P3 and by the production 
of cytokines, such as TGF-β and IL-10. They 
modulate the immune system, maintain tolerance, 
and prevent autoimmune disease. In terms of 
immunosuppressive activity, Treg are able to inhibit 
anti-tumour immune responses and are a negative 
prognostic indicator in various tumours. Treg were 
found in greater numbers in PC tissue than in 
non-tumoural pancreatic stroma,12,36 and higher 
levels of Treg correlated with less differentiated 
tumours.37 Moreover, Treg correlate with metastasis 
and tumour grade, and negatively correlate with 
patient survival.5,36,37
Immunohistochemical assays on PC tissues 
show the presence of both Th1 and Th2 cell 
subpopulations, with the prevalence of the Th2 
subset.38 A recent study39 reported that the 
Th2/Th1 ratio is an independent predictor of 
disease-free and overall survival in PC patients, 
suggesting the implication of Th2 in cancer 
promotion. The pro-tumoural effect of Th2 
polarisation depends on IL-4 production that, 
besides reducing Th1 polarisation, has a direct 
immunosuppressive effect on CD8+ T cells.40
Th22 cells, a T helper subpopulation producing 
IL-22, were first described in patients with 
inflammatory disease but have also been identified 
in many tumours.41,42 Even if the role of Th22 
lymphocytes in the cancer immune response is 
ambiguous, IL-22 seems to play a pro-tumoural role 
in gastrointestinal tumours.42 In PC, the intratumoural 
IL-22 levels and frequency of Th22 cells are elevated 
compared with the peripheral blood of patients 
and healthy donors.43 Moreover, the expression of 
both IL-22 and IL-22R1 is elevated in tissue sections 
of PC.44 Recently, we observed that IL-22-producing 
T cells were significantly increased in PC tissue and 
that this increase was positively correlated with 
tumour, node, and metastasis (TNM) staging and 
poorer patient survival.41 We also demonstrated 
that IL-22 production by intratumoural Th1/Th22 
cells during PC progression may therefore neutralise 
the anti-tumour effect of Th1-polarised T cells, 
protecting the cancer cells by the proapoptotic 
effect of IFN-γ. Moreover, the percentage of 
peripheral blood Th22 cells in PC patients was 
significantly higher compared to age–matched 
healthy donors, demonstrating that monitoring 
circulating Th22 levels could be a good diagnostic 
parameter and blocking IL–22 signalling may 
represent a viable method for innovative 
anti–PC therapies.
Tumour-associated Macrophages 
Frequently, cancers are infiltrated by TAM, 
classically divided into two subsets, M1 and M2. 
M1 macrophages possess proinflammatory and 
tumouricidal capabilities, while M2 are specialised to 
suppress inflammation and repair damaged tissues. 
TAM seem crucial in mediating PC immune escape. 
Kurahara et al.45 suggested that increased M2-type 
infiltration might support the lymph-angiogenesis 
and lymphatic metastatic spread in PC; moreover, 
PC patients that display a high TAM infiltration had 
a significantly poorer prognosis. In accordance, 
Ino et al.5 showed that high CD163+ and CD204+ cell 
infiltration correlated with a reduced disease-free 
and overall survival in 212 PC patients. Recently, 
it has been demonstrated that the depletion of a 
specific extratumoural macrophage population can 
enhance CD8+ T-cell tumour infiltration in response 
to CD40 agonist immunotherapy46 and, furthermore, 
Rosati et al.47 showed that the blocking of 
macrophage activation leads to diminishing primary 
tumour growth and metastasis.
Myeloid-derived Suppressor Cells
MDSC are a heterogeneous population of cells 
defined by their myeloid origin, immature state, 
and ability to potently suppress T cell responses. 
Where MDSC are missing in the normal pancreas, 
they are quickly recruited to the PC stroma, 
where they can represent >60% of the infiltrating 
leukocytes.48 In a spontaneous PC mouse model, 
Zhao et al.49 have shown that, in the pre-malignant 
lesion stage, MDSC count is increased in the lymph 
nodes, blood, and pancreas, and that this increment 
becomes greater upon tumour development. 
In vitro, MDSC were capable of suppressing 
T lymphocyte responses. More recently, MDSC 
infiltration was correlated with decreased levels of 
CTL and T helper cells and increased levels of Treg 
in the blood of mice after subcutaneous injection of 
the non-metastatic PC cell line, Pan02. Furthermore, 
MDSC were able to suppress CTL in vitro and induce 
initial cancer growth.48 Indeed, in the KrasLSL.
G12D/+; p53R172H/+; PdxCretg/+ (KPC) model of 
metastatic PC, MDSC correlated with cancer cells 
and metastases, suppressed T cell proliferation, 
and expressed high levels of arginase and nitrite 
upon stimulation.50 Gabitass et al.51 showed that 
in 46 PC patients, MDSC levels correlated with a 
Th2 skewing for cytokine production, in particular 
for IL-13 and, moreover, a high concentration of 
MDSC in the peripheral blood was associated with 
poor outcomes. 
Mast Cells
The role of mast cells (MC), a type of granulocyte 
derived from the myeloid stem cell, in cancer 
is not well-defined,18 but it is known that 
MC are a consistent component of the tumour 
microenvironment in different human cancers and, 
depending on the tumour, MC counts have been 
associated with either favourable or poor prognosis. 
In patients with PC, MC numbers were significantly 
increased in tumour tissue compared to the 
non-tumoural pancreas and their count correlated 
with lymph nodes’ metastases and intratumour 
microvessel density; furthermore, patients with 
a low count of infiltrating MC tended to survive 
longer than those with elevated numbers.52 More 
recent research,53 conducted on 53 PC patients, 
showed that a massive MC infiltration was present 
in higher grade tumours and recurrence-free and 
disease-specific survival was worse in patients with 
high numbers of MC than those with a lower MC 
count. In another study, comprising 67 PC tissue 
samples, high infiltration of MC was confirmed as a 
negative predictive marker of patient survival.54 
CONCLUSION
Immunotherapy appears to be a promising 
treatment for cancer, including PC.55,56 Currently, 
many clinical trials for PC treatment are ongoing, 
based on synthetic, cellular-based, autologous 
and allogeneic vaccines, adoptive T-cell transfer, 
and combination therapies. However, many of 
these approaches, designed to prompt or increase 
the anti-tumoural immune response, failed due 
to the immunosuppressive microenvironment 
that characterises PC. Indeed, in evaluating the 
opportunity of immune-based therapies, it is 
crucial to remember that from an early stage in PC 
progression, the capacity of the immune system to 
1. de Castro SM et al. Validation of a 
nomogram for predicting survival after 
resection for adenocarcinoma of the 
pancreas. Br J Surg. 2009;96(4):417-23.
2. Dunn GP et al. Cancer immunoediting: 
from immunosurveillance to tumor 
escape. Nat Immunol. 2002;3(11):991-8.
3. Collins MA et al. Oncogenic Kras 
is required for both the initiation and 
maintenance of pancreatic cancer in mice. 
J Clin Invest. 2012;122(2):639-53.
4. Raimondi S et al. Pancreatic cancer in 
chronic pancreatitis; aetiology, incidence, 
and early detection. Best Pract Res Clin 
Gastroenterol. 2010;24(3):349-58.
5. Ino Y et al. Immune cell infiltration 
as an indicator of the immune 
microenvironment of pancreatic cancer. 
Br J Cancer. 2013;108(4):914-23.
6. Fridman WH et al. The immune 
contexture in human tumours: impact 
on clinical outcome. Nat Rev Cancer. 
2012;12(4):298-306.
7. Feig C et al. The pancreas cancer 
microenvironment. Clin Cancer Res. 2012; 
18(16):4266-76.
8. Clark CE et al. Dynamics of the 
immune reaction to pancreatic cancer 
from inception to invasion. Cancer Res. 
2007;67(19):9518-27. 
9. Fukunaga A et al. CD8+ tumor-
infiltrating lymphocytes together with 
CD4+ tumor-infiltrating lymphocytes and 
dendritic cells improve the prognosis of 
patients with pancreatic adenocarcinoma. 
Pancreas. 2004;28(1):e26-31.
10. Heller A et al. Immunogenicity of 
SEREX-identified antigens and disease 
outcome in pancreatic cancer. Cancer 
Immunol Immunother. 2010;59(9): 
1389-400.
11. Cappello P et al. An integrated 
humoral and cellular response is elicited 
in pancreatic cancer by alpha-enolase, a 
novel pancreatic ductal adenocarcinoma-
associated antigen. Int J Cancer. 2009; 
125(3):639-48.
12. Amedei A et al. Ex vivo analysis 
of pancreatic cancer-infiltrating T 
lymphocytes reveals that ENO-specific 
Tregs accumulate in tumor tissue 
and inhibit Th1/Th17 effector cell 
functions. Cancer Immunol Immunother. 
2013;62(7):1249-60.
13. Niccolai E et al. Peripheral ENO1-
specific T cells mirror the intratumoral 
immune response and their presence 
is a potential prognostic factor for 
pancreatic adenocarcinoma. Int J Oncol. 
2016;49(1):393-401.
14. von Bernstorff W et al. Systemic and 
Local Immunosuppression in Pancreatic 
Cancer Patients. Clin Cancer Res. 2001; 
7(3 Suppl):925s-932s.
15. Schumacher TN, Schreiber RD. 
Neoantigens in cancer immunotherapy. 
Science. 2015;348(6230):69-74.
16. Vonderheide RH, Bayne LJ. 
Inflammatory networks and immune 
surveillance of pancreatic carcinoma. 
Curr Opin Immunol. 2013;25(2):200-5.
17. Ademmer K et al. Effector T lymphocyte 
subsets in human pancreatic cancer: 
detection of CD8+ CD18+ cells and CD8+ 
CD103+ cells by multi-epitope imaging. 
Clin Exp Immunol. 1998;112(1):21-6.
18. Protti MP, De Monte L. Immune 
infiltrates as predictive markers of 
survival in pancreatic cancer patients. 
Front Physiol. 2013;4:210.
19. Ostrand-Rosenberg S. Immune 
surveillance: a balance between protumor 
and antitumor immunity. Curr Opin Genet 
Dev. 2008;18(1):11-8.
20. Joyce JA, Pollard JW. 
Microenvironmental regulation of 
metastasis. Nat Rev Cancer. 2009;9(4): 
239-52.
21. Galon J et al. Type, density, and location 
of immune cells within human colorectal 
tumors predict clinical outcome. Science. 
2006;313(5795):1960-4.
22. He S et al. Distribution and clinical 
significance of Th17 cells in the tumor 
microenvironment and peripheral blood 
of pancreatic cancer patients. Int J Mol 
Sci. 2011;12(11):7424-37.
23. Veldhoen M et al. Transforming 
growth factor-beta ‘reprograms’ the 
differentiation of T helper 2 cells and 
promotes an interleukin 9-producing 
subset. Nat Immunol. 2008;9(12):1341-6.
24. Purwar R et al. Robust tumor 
immunity to melanoma mediated by 
interleukin-9-producing T cells. Nat Med. 
2012;18(8):1248-53.
25. Lu Y et al. Th9 cells promote antitumor 
immune responses in vivo. J Clin Invest. 
2012;122(11):4160-71.
26. Berzofsky JA, Terabe M. NKT cells in 
tumor immunity: opposing subsets define 
a new immunoregulatory axis. J Immunol. 
2008;180(6):3627-35.
27. Giaccone G et al. A phase I study of 
the natural killer T-cell ligand alpha-
galactosylceramide (KRN7000) in 
patients with solid tumors. Clin Cancer 
Res. 2002;8(12):3702-9.
28. Nagaraj S et al. Dendritic cells 
pulsed with alpha-galactosylceramide 
induce anti-tumor immunity against 
pancreatic cancer in vivo. Int Immunol. 
2006;18(8):1279-83.
29. Sojka DK et al. Tissue-resident natural 
killer cells and their potential diversity. 
Semin Immunol. 2014;26(2):127-31.
30. Spits H et al. Innate lymphoid cells–a 
proposal for uniform nomenclature. Nat 
Rev Immunol. 2013;13(2):145-9.
31. Pandha H et al. Loss of expression of 
antigen-presenting molecules in human 
pancreatic cancer and pancreatic cancer 
cell lines. Clin Exp Immunol. 2007; 
148(1):127-35.
32. Duan X et al. Clinical significance 
of the immunostimulatory MHC class I 
chain-related molecule A and NKG2D 
receptor on NK cells in pancreatic cancer. 
Med Oncol. 2011;28(2):466-74.
33. Davis M et al. Effect of pemetrexed 
on innate immune killer cells and 
adaptive immune T cells in subjects 
with adenocarcinoma of the pancreas. 
J Immunother. 2012;35(8):629-40.
34. Toyokawa H et al. Enhancement 
of circulating dendritic cell activity by 
immunomodulators (OK432 and KP-40). 
Anticancer Res. 2002;22(4):2137-45.
35. Yamamoto T et al. Circulating myeloid 
dendritic cells as prognostic factors in 
patients with pancreatic cancer who have 
undergone surgical resection. J Surg Res. 
2012;173(2):299-308.
REFERENCES
recognise and eliminate tumoural cells is impaired, 
due to the ability of PC cells to affect both arms 
of the immune response (immune activation 
and suppression) and taking into account that 
unspecified immunotherapeutic approaches also 
led to the stimulation of immune suppression. In 
conclusion, future concepts of PC immunotherapy 
should be designed based on the elimination 
of immune suppression. In order to perform an 
effective therapeutic strategy, it is necessary to 
increase the density of intratumoural effectors 
T cells, decrease or inhibit suppressor immune 
cells and receptors, and understand the role of 
stromal reaction and its interaction with PC immune 
microenvironment.
36. Hiraoka N et al. Prevalence of FOXP3+ 
regulatory T cells increases during 
the progression of pancreatic ductal 
adenocarcinoma and its premalignant 
lesions. Clin Cancer Res. 2006;12(18): 
5423-34.
37. Yamamoto T et al. Circulating 
CD4+CD25+ regulatory T cells in patients 
with pancreatic cancer. Pancreas. 2012; 
41(3):409-15.
38. Tassi E et al. Carcinoembryonic 
antigen-specific but not antiviral CD4+ 
T cell immunity is impaired in pancreatic 
carcinoma patients. J Immunol. 2008; 
181(9):6595-603.
39. De Monte L et al. Intratumor T helper 
type 2 cell infiltrate correlates with 
cancer-associated fibroblast thymic 
stromal lymphopoietin production and 
reduced survival in pancreatic cancer. 
J Exp Med. 2011;208(3):469-78.
40. Kemp RA, Ronchese F. Tumor-specific 
Tc1, but not Tc2, cells deliver protective 
antitumor immunity. J Immunol. 2001; 
167(11):6497-502.
41. Niccolai E et al. Intra-tumoral IFN-
gamma-producing Th22 correlate with 
TNM staging and worst outcome in 
human pancreatic cancer. Clin Sci (Lond). 
2016;130(4):247-58.
42. Zhuang Y et al. Increased intratumoral 
IL-22-producing CD4+ T cells and 
Th22 cells correlate with gastric cancer 
progression and predict poor patient 
survival. Cancer Immunol Immunother. 
2012;61(11):1965-75.
43. Xu X et al. Increased intratumoral 
interleukin 22 levels and frequencies 
of interleukin 22-producing CD4+ T 
cells correlate with pancreatic cancer 
progression. Pancreas. 2014;43(3):470-7.
44. Wen Z et al. High expression of 
interleukin-22 and its receptor predicts 
poor prognosis in pancreatic ductal 
adenocarcinoma. Ann Surg Oncol. 2014; 
21(1):125-32.
45. Kurahara H et al. M2-polarized tumor-
associated macrophage infiltration of 
regional lymph nodes is associated with 
nodal lymphangiogenesis and occult 
nodal involvement in pN0 pancreatic 
cancer. Pancreas. 2013;42(1):155-9.
46. Beatty GL et al. Exclusion of T 
cells from pancreatic carcinomas 
in mice is regulated by Ly6C(low) 
F4/80(+) extratumoral macrophages. 
Gastroenterology. 2015;149(1):201-10.
47. Rosati A et al. BAG3 promotes 
pancreatic ductal adenocarcinoma growth 
by activating stromal macrophages. Nat 
Commun. 2015;6:8695.
48. Porembka MR et al. Pancreatic 
adenocarcinoma induces bone marrow 
mobilization of myeloid-derived 
suppressor cells which promote 
primary tumor growth. Cancer Immunol 
Immunother. 2012;61(9):1373-85.
49. Zhao F et al. Increase in frequency of 
myeloidderived suppressor cells in mice 
with spontaneous pancreatic carcinoma. 
Immunology. 2009;128(1):141-9.
50. Bayne LJ et al. Tumor-derived 
granulocytemacrophage colony-
stimulating factor regulates myeloid 
inflammation and T cell immunity in 
pancreatic cancer. Cancer Cell. 2012;21(6): 
822-35.
51. Gabitass RF et al. Elevated myeloid-
derived suppressor cells in pancreatic, 
esophageal and gastric cancer are an 
independent prognostic factor and are 
associated with significant elevation of 
the Th2 cytokine interleukin-13. Cancer 
Immunol Immunother. 2011;60(10): 
1419-30.
52. Esposito I et al. Inflammatory cells 
contribute to the generation of an 
angiogenic phenotype in pancreatic 
ductal adenocarcinoma. J Clin Pathol. 
2004;57(6):630-6.
53. Strouch MJ et al. Crosstalk between 
mast cells and pancreatic cancer 
cells contributes to pancreatic tumor 
progression. Clin Cancer Res. 2010; 
16(8):2257-65.
54. Chang DZ et al. Mast cells in tumor 
microenvironment promotes the in 
vivo growth of pancreatic ductal 
adenocarcinoma. Clin Cancer Res. 2011; 
17(22):7015-23.
55. Niccolai E et al. What is recent in 
pancreatic cancer immunotherapy? 
Biomed Res Int. 2013;2013:492372.
56. Zhang Y, Choi M. Immune therapy in 
pancreatic cancer: now and the future? 
Rev Recent Clin Trials. 2015;10(4):317-25.
